NCT02696135 The Chinese Hypertrophic Cardiomyopathy Study(CHCS)
| NCT ID | NCT02696135 |
| Status | Recruiting |
| Phase | — |
| Sponsor | China National Center for Cardiovascular Diseases |
| Condition | Cardiomyopathy, Hypertrophic |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2011-03-23 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2011-03-23 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, with a prevalence of ∼0.2%. Sudden cardiac death (SCD), heart failure and stroke are the major poor outcomes of HCM. Although about half of the patients were found to be caused by mutations mainly located in genes encoding sarcomere proteins, the causes in a significant proportion of patients with HCM are still unknown. Even in the patients with sarcomere mutations, the molecular pathways that eventually lead to cardiac hypertrophy are remained to be revealed. Furthermore, HCM presents with significant heterogeneity. SCD risk stratification and prevention by ICD are necessary. However, the strategy of SCD risk stratification recommended by the 2011 ACCF/AHA and 2014 ESC guidelines were based mainly on the evidence derived from American and European countries. The accuracy of these guidelines in Chines patients with HCM was not evaluated yet.
Eligibility Criteria
Inclusion criteria: Patients with HCM diagnosed by observation of unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and/or cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM. Exclusion criteria: Individuals with other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy.
Contact & Investigator
Song Lei, MD.&ph.D
PRINCIPAL INVESTIGATOR
Chinese Academy of Medical Sciences, Fuwai Hospital
Frequently Asked Questions
Who can join the NCT02696135 clinical trial?
This trial is open to participants of all sexes, studying Cardiomyopathy, Hypertrophic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02696135 currently recruiting?
Yes, NCT02696135 is actively recruiting participants. Contact the research team at clinicalfw@163.com for enrollment information.
Where is the NCT02696135 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT02696135 clinical trial?
NCT02696135 is sponsored by China National Center for Cardiovascular Diseases. The principal investigator is Song Lei, MD.&ph.D at Chinese Academy of Medical Sciences, Fuwai Hospital. The trial plans to enroll 3,000 participants.